

Tumor treating Fields as the novel standard of care for GBM Fourth Modality on Cancer Therapy

Clinical training and education

May 9TH 2019

LIPSET AUDITORIUM BLDG 10
NATIONAL INSTITUTE OF HEALTH

CLINICAL CENTER

*9000 Rockville Avenue
Bethesda, Maryland
USA*

May 9th **Opening ceremony**
Remarks TBD DCTD/Dr. Jonathan Wiest CCT
8:00-9:00 **Dr. Robert Lembo, Director Office of Clinical Education and training
Clinical Center NIH.**

I)Introduction Tumor Treating Fields

**Chair: TBD Application of tumor treating fields for newly diagnosed
glioblastoma: understanding of nationwide practice patterns**

Dr. Jerry Daboin

Department of Radiation Medicine Oregon Health & Science University
Portland USA

**TBD: Efficacy of treating electrical fields therapy to treat brain
tumors**

9:00-9:30 Dr. Patrick Wen
Past President Society of Neuro-Oncology
Professor of Neurology, Harvard Medical School
Director, Center for Neuro-Oncology
Dana-Farber Cancer Institute

9:30-10:00 **TTF efficacy over temozolomide for GBM EF12 trial**

Dr. Suriya
Neurosurgeon, Head of Neuro-Oncology Tufts
Medical Center , Boston MA

10:05-10:30 **Coffee break**

10:05-10:30 **TBD New modalities to image brain tumors at the Clinical Center.**

Dr. John Butman

Head Neuro-Radiology Unit
Clinical Center NIH

10:30-11:00 **Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma**

Dr. Andreas Hottinger

Head of Neuro-Oncology

Centre Hospitalaire Lausanne Switzerland

11:00-11:30 **Development of Multicentric trial using TTF for GBM**

Dr. Jai Grewal and Eilon Kirston
Haifa University Israel

11:30-12:00 **Tumor treating fields mechanism of action**

Dr. Moshe Giladi
Director of Technology
Novocure, Haifa Israel

The future of TTFields in GBM and beyond

12:00-12:30

Dr. Uri Weinberg

VP Clinical Development, Novocure USA

Alternating Electric Fields (TTFields) Activate Cav1.2 Channels in Human Glioblastoma Cells

Dr. Stephan Huber

12:30-13:00 Department of Radiation Oncology

German Cancer Consortium(DKTK) partnersite Tübingen, German
Cancer Research Center (DKFZ) Germany

**Chair: Dr. Pedro del Valle Office of Hematology and Oncology
Products, Office of New Drugs, Center for Drug Evaluation and
Research FDA**

- 12:30-13:00 **TBD: TTF for unresectable tumors and combining novel existing chemotherapy**
Dr. Larry Lo
Head Spine Neurosurgery Johns Hopkins SOM
- 13:00-13:30 **Combining Repurposed Agents with TTF to treat GBM**
Dr. Greg Riggins
Research Chair
Department of Neurosurgery Johns Hopkins
- 13:30- 14:00 **TTF as integrative solution for treating GBM patients**
Dr. Joshua Palmer
Department of Neuro-Oncology, The Ohio State University, Columbus.
- 14:00- 14:30 **Stereotactic Radiosurgery and TTF on recurrent GBM**
Dr. Young Kwok
Maryland Proton Center and Radiation Oncology
- 14:00- 14:30 **Dosimetric impact of tumor treating field (TTField) transducer arrays onto treatment plans for glioblastomas**
Dr. Chris Straub
Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich (TUM), 81675, Munich, Germany.
- 14:30- 15:00 **TTF therapy on Pancreatic Adenocarcinoma and Lung Cancer**
Dr.Hani Babiker

Clinical Trials Unit
University of Arizona Cancer Center
- MRI analysis on 7T: Biomarkers on effectiveness for TTF therapy**
Dr. Mohed
Neuro-Radiology Department
Penn University
- 15:00- 15:30 **Round table discussion Speakers**

16:00 Adjourn

[Type here]